Bone Characteristics Of Broiler Chickens Fed Diets Supplemented With Solanum Glaucophyllum

The aim of this study was to assess the characteristics of the tibiotarsus of male broilers at 21 and 35 days of age. The percentages of collagenous proteins (CP), non-collagenous proteins (NCP), ash, and minerals (calcium, phosphorus, potassium and sodium), as well as weight of dried and defatted tibiotarsus in natura were determined. A total of 648 Cobb® male broilers were used in a random block design study with 6 treatments, 6 replicates, and 18 birds per experimental unit. The treatments consisted of diet supplementation with 0.0, 0.5, 1.0, 1.5, 2.0, and 2.5 μg of active Vitamin D3 per kg of feed. The birds were weighed at 21 and 35 days of age and one bird per repetition with the mean weight of the experimental unit was slaughtered to collect the tibiotarsus. The organic and mineral composition of the bone was affected by the addition of active Vitamin D3 to the feed. Our results indicate that a dose of up to 1.50 μg of 1,25(OH)2D3/kg of feed is ideal for male broilers between 8 and 35 days of age.37138139

Kinase Inhibitor Profile For Human Nek1, Nek6, And Nek7 And Analysis Of The Structural Basis For Inhibitor Specificity

Human Neks are a conserved protein kinase family related to cell cycle progression and cell division and are considered potential drug targets for the treatment of cancer and other pathologies. We screened the activation loop mutant kinases hNek1 and hNek2, wild-type hNek7, and five hNek6 variants in different activation/phosphorylation statesand compared them against 85 compounds using thermal shift denaturation. We identified three compounds with significant Tm shifts: JNK Inhibitor II for hNek1(Ä262-1258)-(T162A), Isogranulatimide for hNek6(S206A), and GSK-3 Inhibitor XIII for hNek7wt. Each one of these compounds was also validated by reducing the kinases activity by at least 25%. The binding sites for these compounds were identified by in silico docking at the ATP-binding site of the respective hNeks. Potential inhibitors were first screened by thermal shift assays, had their efficiency tested by a kinase assay, and were finally analyzed by molecular docking. Our findings corroborate the idea of ATP-competitive inhibition for hNek1 and hNek6 and suggest a novel non-competitive inhibition for hNek7 in regard to GSK-3 Inhibitor XIII. Our results demonstrate that our approach is useful for finding promising general and specific hNekscandidate inhibitors, which may also function as scaffolds to design more potent and selective inhibitors.20111761191Rubin, G.M., Yandell, M.D., Wortman, J.R., Gabor Miklos, G.L., Nelson, C.R., Hariharan, I.K., Fortini, M.E., Fleischmann, W., Comparative genomics of the eukaryotes (2000) Science, 287, pp. 2204-2215Johnson, L.N., Lowe, E.D., Noble, M.E., Owen, D.J., The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases (1998) FEBS Lett., 430, pp. 1-11Hanks, S.K., Eukaryotic protein kinases (1991) Curr. Opin. Struct. Biol., 1, pp. 369-383Jeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massagué, J., Pavletich, N.P., Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex (1995) Nature, 376, pp. 313-320Yamaguchi, H., Hendrickson, W.A., Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation (1996) Nature, 384, pp. 484-489Canagarajah, B.J., Khokhlatchev, A., Cobb, M.H., Goldsmith, E.J., Activation mechanism of the MAP kinase ERK2 by dual phosphorylation (1997) Cell, 90, pp. 859-869Hubbard, S.R., Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog (1997) EMBO J, 16, pp. 5572-5581Fry, A.M., O'Regan, L., Sabir, S.R., Bayliss, R., Cell cycle regulation by the NEK family of protein kinases (2012) J. Cell Sci., 125, pp. 4423-4433Meirelles, G.V., Perez, A.M., Souza, E.E., Basei, F.L., Papa, P.F., Melo Hanchuk, T.D., Cardoso, V.B., Kobarg, J., "Stop Ne(c)king around": How systems biology can help to characterize the functions of Nek family kinases from cell cycle regulation to DNA damage response (2014) World J. Biol. Chem., 5, pp. 141-160Fry, A.M., Mayor, T., Meraldi, P., Stierhof, Y.D., Tanaka, K., Nigg, E.A., C-Nap1, a novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated protein kinase Nek2 (1998) J. Cell Biol., 141, pp. 1563-1574Quarmby, L.M., Mahjoub, M.R., Caught nek-ing: Cilia and centrioles (2005) J. Cell Sci., 118, pp. 5161-5169Meirelles, G.V., Silva, J.C., Mendonça, Y.A., Ramos, C.H., Torriani, I.L., Kobarg, J., Human Nek6 is a monomeric mostly globular kinase with an unfolded short N-terminal domain (2011) BMC Struct. Biol., 11, p. 12Belham, C., Roig, J., Caldwell, J.A., Aoyama, Y., Kemp, B.E., Comb, M., Avruch, J., A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases (2003) J. Biol. Chem., 278, pp. 34897-34909Yin, M.J., Shao, L., Voehringer, D., Smeal, T., Jallal, B., The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis (2003) J. Biol. Chem., 278, pp. 52454-52460Yissachar, N., Salem, H., Tennenbaum, T., Motro, B., Nek7 kinase is enriched at the centrosome, and is required for proper spindle assembly and mitotic progression (2006) FEBS Lett., 580, pp. 6489-6495Kim, S., Lee, K., Rhee, K., NEK7 is a centrosomal kinase critical for microtubule nucleation (2007) Biochem. Biophys. Res.Commun., 360, pp. 56-62Roig, J., Mikhailov, A., Belham, C., Avruch, J., Nercc1, a mammalian NIMA-family kinase, binds the Ran GTPase and regulates mitotic progression (2002) Genes Dev., 16, pp. 1640-1658Upadhya, P., Birkenmeier, E.H., Birkenmeier, C.S., Barker, J.E., Mutations in a NIMA-related kinase gene, Nek1, cause pleiotropic effects including a progressive polycystic kidney disease in mice (2000) Proc. Natl. Acad. Sci. USA, 97, pp. 217-221Liu, S., Lu, W., Obara, T., Kuida, S., Lehoczky, J., Dewar, K., Drummond, I.A., Beier, D.R., A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish (2002) Development, 129, pp. 5839-5846Chen, J., Li, L., Zhang, Y., Yang, H., Wei, Y., Zhang, L., Liu, X., Yu, L., Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients (2006) Biochem. Biophys. Res. Commun., 341, pp. 1059-1065Chen, Y., Chen, P.L., Chen, C.F., Jiang, X., Riley, D.J., Never-in mitosis related kinase 1 functions in DNA damage response and checkpoint control (2008) Cell Cycle, 7, pp. 3194-3201Lee, M.Y., Kim, H.J., Kim, M.A., Jee, H.J., Kim, A.J., Bae, Y.S., Park, J.I., Yun, J., Nek6 is involved in G2/M phase cell cycle arrest through DNA damage induced phosphorylation (2008) Cell Cycle, 7, pp. 2705-2709Innocenti, P., Cheung, K.M., Solanki, S., Mas-Droux, C., Rowan, F., Yeoh, S., Boxall, K., Hardy, T., Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: Structure-activity relationship, structural biology, and cellular activity (2012) J. Med. Chem., 55, pp. 3228-3241Solanki, S., Innocenti, P., Mas-Droux, C., Boxall, K., Barillari, C., Van Montfort, R.L., Aherne, G.W., Hoelder, S., Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure-activity relationship (2011) J. Med. Chem., 54, pp. 1626-1639Whelligan, D.K., Solanki, S., Taylor, D., Thomson, D.W., Cheung, K.M., Boxall, K., Mas-Droux, C., Grummitt, C.G., Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization (2010) J. Med. Chem., 53, pp. 7682-7698Srinivasan, P., ChellaPerumal, P., Sudha, A., Discovery of novel inhibitors for Nek6 protein through homology model assisted structure based virtual screening and molecular docking approaches (2014) Sci. World J., 2014. , ID: 967873Rellos, P., Ivins, F.J., Baxter, J.E., Pike, A., Nott, T.J., Parkinson, D.M., Das, S., Shen, Q.Y., Structure and regulation of the human Nek2 centrosomal kinase (2007) J. Biol. Chem., 282, pp. 6833-6842Westwood, I., Cheary, D.M., Baxter, J.E., Richards, M.W., Van Montfort, R.L., Fry, A.M., Bayliss, R., Insights into the conformational variability and regulation of human Nek2 kinase (2009) J. Mol. Biol, 386, pp. 476-485Richards, M.W., O'Regan, L., Mas-Droux, C., Blot, J.M., Cheung, J., Hoelder, S., Fry, A.M., Bayliss, R., An autoinhibitory tyrosine motif in the cell-cycleregulated Nek7 kinase is released through binding of Nek9 (2009) Mol. Cell, 36, pp. 560-570Geromichalos, G.D., Importance of molecular computer modeling in anticancer drug development (2007) J. Buon., 12, pp. S101-S118Vedadi, M., Niesen, F.H., Allali-Hassani, A., Fedorov, O.Y., Finerty, P.J., Jr., Wasney, G.A., Yeung, R., Berglund, H., Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 15835-15840Lengauer, T., Rarey, M., Computational methods for biomolecular docking (1996) Curr. Opin. Struct. Biol., 6, pp. 402-406Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A.N., Schwaller, J., Knapp, S., A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases (2007) Proc. Natl. Acad. Sci. USA, 104, pp. 20523-20528Roberge, M., Berlinck, R.G., Xu, L., Anderson, H.J., Lim, L.Y., Curman, D., Stringer, C.M., Vincent, I., High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide (1998) Cancer Res, 58, pp. 5701-5706Jiang, X., Zhao, B., Britton, R., Lim, L.Y., Leong, D., Sanghera, J.S., Zhou, B.B., Roberge, M., Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide (2004) Mol. Cancer Ther., 3, pp. 1221-1227De Castro, E., Sigrist, C.J.A., Gattiker, A., Bulliard, V., Langendijk-Genevaux, P.S., Gasteiger, E., Bairoch, A., Hulo, N., ScanProsite: Detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins (2006) Nucleic Acids Res., 34, pp. W362-W365Gavrin, L.K., Saiah, E., Approaches to discover non-ATP site kinase inhibitors (2013) Med. Chem. Commun., 4, pp. 41-51Oliveira, S.H., Ferraz, F.A., Honorato, R.V., Xavier-Neto, J., Sobreira, T.J., De Oliveira, P.S., KVFinder: Steered identification of protein cavities as a PyMOL plugin (2014) BMC Bioinform., 15, p. 197Meirelles, G.V., Lanza, D.C.F., Silva, J.C., Bernachi, J.S., Leme, A.F.P., Kobarg, J., Characterization of hNek6 Interactome Reveals an Important Role for Its Short N-Terminal Domain and Colocalization with Proteins at the Centrosome (2010) J. Proteome Res., 9, pp. 6298-6316Trott, O., Olson, A.J., AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading (2010) J. Comput. Chem., 31, pp. 455-46

Genomic analysis of two phlebotomine sand fly vectors of Leishmania from the New and Old World.

Phlebotomine sand flies are of global significance as important vectors of human disease, transmitting bacterial, viral, and protozoan pathogens, including the kinetoplastid parasites of the genus Leishmania, the causative agents of devastating diseases collectively termed leishmaniasis. More than 40 pathogenic Leishmania species are transmitted to humans by approximately 35 sand fly species in 98 countries with hundreds of millions of people at risk around the world. No approved efficacious vaccine exists for leishmaniasis and available therapeutic drugs are either toxic and/or expensive, or the parasites are becoming resistant to the more recently developed drugs. Therefore, sand fly and/or reservoir control are currently the most effective strategies to break transmission. To better understand the biology of sand flies, including the mechanisms involved in their vectorial capacity, insecticide resistance, and population structures we sequenced the genomes of two geographically widespread and important sand fly vector species: Phlebotomus papatasi, a vector of Leishmania parasites that cause cutaneous leishmaniasis, (distributed in Europe, the Middle East and North Africa) and Lutzomyia longipalpis, a vector of Leishmania parasites that cause visceral leishmaniasis (distributed across Central and South America). We categorized and curated genes involved in processes important to their roles as disease vectors, including chemosensation, blood feeding, circadian rhythm, immunity, and detoxification, as well as mobile genetic elements. We also defined gene orthology and observed micro-synteny among the genomes. Finally, we present the genetic diversity and population structure of these species in their respective geographical areas. These genomes will be a foundation on which to base future efforts to prevent vector-borne transmission of Leishmania parasites

Measurements of differential production cross sections for a Z boson in association with jets in pp collisions at root s=8 TeV

Peer reviewe